JUBLPHARMA1,026.00

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹16,211 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity1.4213.455.625.62
Return on Assets0.636.562.562.56
Return on Capital Employed5.377.606.316.31
Return on Invested Capital2.639.055.865.32
Margins
EBITDA Margin13.4416.2215.2214.15
Operating Margin7.7411.139.909.90
Incremental Operating Margin53.841.37
Pretax Margin2.1813.567.426.35
Net Income Margin1.0811.564.804.08
Net Income to Common Margin1.1511.604.814.09
FCF Margin1.10-0.60-2.68-2.68
Additional
Effective Tax Rate66.8014.7135.2535.64
Dvd Payout Ratio109.779.5220.00
Sustainable Growth Rate-0.1412.174.505.62
Incremental Operating Margin %53.841.37-21.54
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.